Immunocore Aims For $100m IPO After Immunotherapy Success

Proof-Of-Concept For TCR platform

 
• By Andrew McConaghie
  
Nasdaq ipo
The UK-headquartered biotech is set to debut on the NASDAQ exchange shortly.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Archive

More from Scrip